Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.51 |
| ▸ | PHGDH | O43175 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 2/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL289579 | 1.00 | P2RX7 (0.51) | P2RX7PHGDHMEN1KMT2AHDAC6 | |
| SCHEMBL630463 | 1.00 | P2RX7 (0.51) | P2RX7PHGDHMEN1KMT2AHDAC6 | |
| SCHEMBL13284935 | 0.86 | ESR1 (0.46) | P2RX7PHGDHKMT2AHDAC6PTGER3 | |
| SCHEMBL28820301 | 0.86 | P2RX7 (0.49) | P2RX7PHGDHMEN1KMT2AHDAC6 | |
| SCHEMBL19974671 | 0.86 | P2RX7 (0.49) | P2RX7PHGDHMEN1KMT2AHDAC6 | |
| SCHEMBL2572998 | 0.85 | CNR2 (0.52) | P2RX7PHGDHNOTUMPTGER3PTGER2 | |
| SCHEMBL9108663 | 0.85 | KMT2A (0.51) | PHGDHMEN1KMT2APTGER3PTGER2 | |
| SCHEMBL22798990 | 0.85 | PHGDH (0.43) | P2RX7PHGDHMEN1KMT2APTGER3 | |
| SCHEMBL9106845 | 0.85 | TDP1 (0.53) | P2RX7PHGDHKMT2AHDAC6NOTUM | |
| SCHEMBL9108668 | 0.85 | KMT2A (0.51) | PHGDHMEN1KMT2APTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-118063371-A | 5-Oxo pyrrolidine-2-carboxylate derivative, preparation method thereof, application in preparation of repellent and antifeedant | 河南农业大学 | 2024-05-24 | — | — | CN | disclosed |
| US-11377443-B2 | Pharmaceutical compounds | CellCentric Limited (GB) | 2022-07-05 | — | — | US | disclosed |
| CN-110049983-B | Pharmaceutical compounds | 细胞中心有限公司 | 2022-06-14 | — | — | CN | disclosed |
| US-20200407349-A1 | PHARMACEUTICAL COMPOUNDS | CellCentric Limited (GB) | 2020-12-31 | — | — | US | disclosed |
| EP-3529248-B1 | PHARMACEUTICAL COMPOUNDS | CELLCENTRIC LTD (GB) | 2020-08-19 | — | — | EP | disclosed |
| US-10696666-B2 | Pharmaceutical compounds | CellCentric Limited (GB) | 2020-06-30 | — | — | US | disclosed |
| EP-2427429-B1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2017-02-15 | — | — | EP | disclosed |
| US-9527811-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-12-27 | — | — | US | disclosed |
| EP-2419413-B1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-8048907-B2 | Receptor antagonists and their methods of use | GLAXO GROUP LIMITED (GB) | 2011-11-01 | — | — | US | disclosed |
| US-20110086879-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2011-04-14 | — | — | US | disclosed |
| WO-2010128102-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2010-11-11 | — | — | US | disclosed |
| US-20100144829-A1 | Novel Receptor Antagonists and Their Methods of Use | GLAXO GROUP LIMITED | 2010-06-10 | — | — | US | disclosed |
| US-7718693-B2 | Receptor antagonists and their methods of use | GLAXO GROUP LIMITED (GB) | 2010-05-18 | — | — | US | disclosed |
| WO-2009074518-A1 | COMBINATIONS OF PROLINAMIDE P2X7 MODULATORS WITH FURTHER THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| EP-2049478-A1 | SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE | Glaxo Group Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008003697-A1 | SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | P2RX7 1852/4885PHGDH 2287/4885MEN1 4503/4885 |
| US-20200407349-A1 | PHARMACEUTICAL COMPOUNDS | EP300, HDAC1, HDAC11 | P2RX7 2158/4885PHGDH 2647/4885MEN1 1691/4885 |
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | P2RX7, P2RX3, P2RX1 | P2RX7 1/4885PHGDH 2706/4885MEN1 4860/4885 |
| US-20100144829-A1 | Novel Receptor Antagonists and Their Methods of Use | P2RX7, P2RX3, P2RX1 | P2RX7 1/4885PHGDH 2706/4885MEN1 4860/4885 |
| US-20110086879-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | P2RX7 1852/4885PHGDH 2287/4885MEN1 4503/4885 |
| US-11377443-B2 | Pharmaceutical compounds | EP300, HDAC1, HDAC11 | P2RX7 2158/4885PHGDH 2647/4885MEN1 1691/4885 |
| US-10696666-B2 | Pharmaceutical compounds | EP300, HDAC1, HDAC11 | P2RX7 2158/4885PHGDH 2647/4885MEN1 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.